CILETATUG VEDOTIN
UNII 7ER98K4WW9
Substance Identification & Data
This profile provides standardized clinical and technical data for Ciletatug Vedotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 7ER98K4WW9.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2897624-59-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
7ER98K4WW9
2897624-59-6
N/A
Detailed Substance Profile
Preferred Name
CILETATUG VEDOTIN
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13111
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Ciletatug Vedotin
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Ciletatug Vedotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
Common Names & Synonyms
Ciletatug Vedotin
Immunoglobulin G1, anti-(human/Macaca fascicularis/Mus musculus/Canis familiaris/Rattus norvegicus claudin CLDN18.2) (human-Mus musculus monoclonal RC118-B186314B11S γ1-chain), complex with human-Mus musculus monoclonal RC118-B186314B11S κ-chain, dimer, 220′′,220′′′,222,222′,228,228′,231,231′-octakis(thioether) with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
ciletatug vedotin [INN]
immunoglobulin G1-kappa, anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, surfactant associated protein J, SFTPJ) isoform 2], humanized monoclonal antibody, conjugated on an average of four cysteinyl residues to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE) (Ciletatug vedotin)
immunoglobulin G1-kappa, anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, surfactant associated protein J, SFTPJ) isoform 2], humanized monoclonal antibody, conjugated on an average of four cysteinyl residues to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE); H-gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV1-46*01 (86.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHG1*03v (100%) G1m3>G1m17, nG1m1, CH1 K120, CH3 E12, M14 (CH1 R120>K (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-220')-disulfide with L-kappa light chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV2-28*01 (85.1%) -IGKJ4*01 (100%), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (159'), V101 (197')) (114'-220')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of four L-cysteinyl residues on an average among 222, 228, 231, 220', 222'', 228'', 231'' and 220''' with a group consisting of (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin)
